Payment overview · 2025
General Payments
$1,073.36
60 reported records · 20 companies
Healthcare provider profile · identity verified
Lacey Jaye Thurman
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · HOPKINSVILLE, KY · NPI 1558097923
Verified facts
What the public records show
CMS Open Payments records show Lacey Jaye Thurman received $1,073.36 in general payments during 2025 across 60 reported records.
Lilly USA, LLC accounted for 12.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $136.22 | 12.7% | 9 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $131.74 | 12.3% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $119.13 | 11.1% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $101.34 | 9.4% | 6 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $75.53 | 7.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $74.32 | 6.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $66.08 | 6.2% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.44 | 5.2% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $46.10 | 4.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.85 | 3.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.38 | 3.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.98 | 3.2% | 2 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $31.52 | 2.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.67 | 2.4% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $21.04 | 2.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.35 | 1.8% | 1 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $18.45 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.01 | 1.6% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $14.22 | 1.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.99 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,073.36 | 60 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $149.69 | 8 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $131.74 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $101.34 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $87.07 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $75.53 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $60.13 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $54.65 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $46.10 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $36.22 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.58 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $35.38 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.95 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.98 | 2 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $31.52 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $31.52 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $31.52 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $31.52 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.86 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.92 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.97 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.67 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 102 | 29 |
| Omeprazole | Omeprazole | 92 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 28 |
| Losartan Potassium | Losartan Potassium | 81 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 78 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 14 |
| Amlodipine Besylate | Amlodipine Besylate | 65 | 15 |
| Lisinopril | Lisinopril | 62 | 17 |
| Furosemide | Furosemide | 59 | 17 |
| Gabapentin | Gabapentin | 55 | 14 |
| Buspirone Hcl | Buspirone Hcl | 50 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | suppressed |
| Allopurinol | Allopurinol | 43 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 14 |
| Metformin Hcl Er | Metformin Hcl | 40 | 12 |
| Levothyroxine Sodium | Levothyroxine Sodium | 39 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 15 |
| Carvedilol | Carvedilol | 34 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Metformin Hcl | Metformin Hcl | 29 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 29 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 26 | suppressed |
| Meloxicam | Meloxicam | 26 | suppressed |
| Ozempic | Semaglutide | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 11 |
| Potassium Chloride | Potassium Chloride | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Prednisone | Prednisone | 17 | 12 |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,073.36 · 60 records | Lilly USA, LLC | ACCRUFER, AIRSUPRA, CHARTIS CATHETER, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, JARDIANCE, Kerendia, LEQVIO, LifeVest, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, PROLIA, PULMONX CHARTIS TABLET CONSOLE, Prolastin-C Liquid, QULIPTA, REPATHA, Rybelsus, TEZSPIRE, TRELEGY ELLIPTA, Tyvaso, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error